Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Campral | Acamprosate calcium | Alcohol Abstinence | N/A | Complete | ||
| Viread | Tenofovir disoproxil fumarate | HIV infection | N/A | Complete | ||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
| Levemir | Insulin detemir | Diabetes mellitus | Withdrawn | |||
| Azilect | Rasagiline mesylate | Parkinson's disease | N/A | Complete | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | N/A | Complete | ||
| Omnitrope | Somatropin (rDNA origin) | Growth hormone deficiency in children and adults | N/A | Complete | ||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | Cancelled | |||
| Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled |
Last Updated : May 10, 2024